CHIESI

📅 Upcoming

🕒 Recent(90d)

News

• A COPD drug from China draws $115M in venture funding
  Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
  biopharma_dive · 1d ago
• Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
  Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.
  biospace · 9d ago
• After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
  After signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaborat…
  fiercebiotech · 10d ago
• Chiesi to buy KalVista in $1.9B deal for rare disease drug
  The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
  biopharma_dive · 3mo ago
• STAT+: A patent win for Pfizer and BridgeBio
  A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout
  stat · 3mo ago
• Chiesi signs $1.9B deal to acquire KalVista and its approved drug
  Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KAL…
  endpoints · 3mo ago